sur AMOEBA (EPA:ALMIB)
Unanimous green light for Amoéba's active substance in Europe
Amoéba, a green biotechnology specialist based in Chassieu, announced that all 27 European Union member states have unanimously approved its Willaertia magna C2c Maky lysate. This active biocontrol substance would be included in AXPERA, which aims to combat diseases such as grapevine downy mildew. This unanimous support facilitates the product's commercialization in Europe as early as 2026.
The European Food Safety Authority had already published a positive report on this substance in January 2025. This unanimous vote paves the way for official approval by the European Commission.
Amoéba's CEO, Jean-François Doucet, is delighted with this key milestone. The process for obtaining marketing authorization in several European countries is underway.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de AMOEBA